Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GSK | 6-K | neutral | 1/10 | GSK filed a routine monthly total voting rights notification under UK FCA rules, reporting 4,045,395,364 voting rights a | Jul 1, 2026 |
| HYFT | 6-K | neutral | 3/10 | MindWalk Holdings filed a European patent application (EP26187897.9) for its high-dimensional biological data architectu | Jul 1, 2026 |
| NCEL | 6-K | bullish | 7/10 | NewcelX announced a successful Type B Pre-IND meeting with the FDA, receiving favorable feedback on its CMC processes an | Jul 1, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K on July 1, 2026, to furnish an intimation (Exhibit 99.1) to the SEC. The filin | Jul 1, 2026 |
| REX | 8-K | neutral | 3/10 | REX American Resources entered into new employment agreements with its three top executives (Executive Chairman Stuart R | Jul 1, 2026 |
| ABVX | PRESS-RELEASE | bearish | 6/10 | Abivax priced an upsized $800M public offering of 6.4M ADSs at $125 per ADS, a 2.4% premium to VWAP, representing 8% dil | Jul 1, 2026 |
| INMB | 8-K | bearish | 5/10 | Inmune Bio entered into warrant inducement agreements with holders of its April 2024 warrants. Holders exercised 50% of | Jul 1, 2026 |
| HCWB | 8-K | neutral | 4/10 | HCW Biologics resolved $2.8M in disputed accounts payable through two settlements: a $1.1M mechanics lien was satisfied | Jul 1, 2026 |
| GOSS | 8-K | bearish | 5/10 | Gossamer Bio announced the conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 and the ex | Jul 1, 2026 |
| ELAB | 8-K | bullish | 5/10 | NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings Inc. (ELAB), announced positive Phase III results fr | Jul 1, 2026 |
| CRMD | 8-K | neutral | 4/10 | CorMedix Inc. dismissed its independent auditor CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) as its new independe | Jul 1, 2026 |
| ZEOX | 8-K | neutral | 1/10 | ZEO ScientifiX announced a live educational webinar for healthcare professionals on July 22, 2026, discussing the impact | Jul 1, 2026 |
| CELZ | PRESS-RELEASE | neutral | 3/10 | Creative Medical Technology Holdings issued a mid-year CEO update highlighting clinical progress across its Olastrocel ( | Jul 1, 2026 |
| ALLR | 8-K | bullish | 6/10 | Allarity Therapeutics announced the USPTO grant of a key U.S. patent covering its stenoparib-specific DRP companion diag | Jul 1, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion announced a poster presentation at the International Herpesvirus Workshop 2026 for its preclinical CMV vaccine c | Jul 1, 2026 |
| ALVO | 6-K | bullish | 5/10 | Alvotech secured a $75 million term loan facility from GoldenTree Asset Management, adding to a recent $165 million equi | Jul 1, 2026 |
| SXTP | PRESS-RELEASE | neutral | 4/10 | 60 Degrees Pharmaceuticals announced that the independent Data Safety Monitoring Board recommended continuation of its B | Jul 1, 2026 |
| DTIL | 8-K | neutral | 4/10 | Precision BioSciences updated its corporate deck, highlighting PBGENE-HBV clinical data showing a 1-log (10-fold) reduct | Jul 1, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a 6-K furnishing a letter to shareholders regarding the availability of the Integrated Annual Report f | Jul 1, 2026 |
| ABT | ANALYST-UPGRADE | bullish | 3/10 | Baird initiated coverage on Abbott Laboratories (ABT) at Outperform with a $121 price target, implying 33% upside from t | Jul 1, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech secured an additional $75 million term loan from GoldenTree Asset Management at 12.5% interest, maturing Decemb | Jul 1, 2026 |
| CVKD | PRESS-RELEASE | bearish | 5/10 | Cadrenal Therapeutics announced a $3M private placement with H.C. Wainwright, selling 960,000 shares and warrants that c | Jun 30, 2026 |
| ROIV | CLUSTER | neutral | 4/10 | Insider cluster at Roivant Sciences shows $32.32M in open-market sales over 7 days, led by President/CIO Sukhatme and la | Jun 30, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$6.0M in open-market sales across June 29-30, 2026, alongside derivative exercises at $135.4 | Jun 30, 2026 |
| CLYM | 144 | neutral | 3/10 | Insider Aoife Brennan (officer/director) filed a Form 144 indicating intent to sell 30,902 shares of Climb Bio common st | Jun 30, 2026 |
| ADPT | CLUSTER | neutral | 2/10 | Three Adaptive Biotechnologies insiders (a director and both chief commercial officers) sold a total of ~$1.39M in open- | Jun 30, 2026 |
| GALT | CLUSTER | neutral | 3/10 | Two insiders at Galectin Therapeutics (CEO-level CMO and a director) collectively sold $278K worth of GALT stock in a 5- | Jun 30, 2026 |
| BDRX | 6-K | neutral | 2/10 | Biodexa Pharmaceuticals reported the results of its Annual General Meeting held June 30, 2026. Ordinary resolutions 1 th | Jun 30, 2026 |
| ORMP | 8-K | mixed | 5/10 | Oramed Pharmaceuticals extended payment obligations from Scilex Holding Company, covering approximately $29.5M Tranche A | Jun 30, 2026 |
| NGNE | 424B5 | bearish | 6/10 | Neurogene filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded w | Jun 30, 2026 |